US 11,786,578 B2
Modified relaxin polypeptides and their uses
Vadim Kraynov, San Diego, CA (US); Nick Knudsen, Escondido, CA (US); Amha Hewet, San Diego, CA (US); Kristine De Dios, San Diego, CA (US); Jason Pinkstaff, Carlsbad, CA (US); and Lorraine Sullivan, San Diego, CA (US)
Assigned to AMBRX, INC., La Jolla, CA (US)
Filed by AMBRX, INC., La Jolla, CA (US)
Filed on Mar. 3, 2022, as Appl. No. 17/685,658.
Application 17/685,658 is a division of application No. 16/884,639, filed on May 27, 2020, granted, now 11,311,605.
Application 16/884,639 is a division of application No. 16/285,986, filed on Feb. 26, 2019, granted, now 10,751,391, issued on Aug. 25, 2020.
Application 16/285,986 is a division of application No. 15/386,347, filed on Dec. 21, 2016, granted, now 10,253,083, issued on Apr. 9, 2019.
Application 15/386,347 is a division of application No. 13/774,349, filed on Feb. 22, 2013, granted, now 9,567,386, issued on Feb. 14, 2017.
Application 13/774,349 is a continuation in part of application No. 13/212,101, filed on Aug. 17, 2011, granted, now 8,735,539, issued on May 27, 2014.
Claims priority of provisional application 61/374,582, filed on Aug. 17, 2010.
Prior Publication US 2022/0257720 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); A61K 38/22 (2006.01); C07K 14/64 (2006.01)
CPC A61K 38/2221 (2013.01) [C07K 14/64 (2013.01)] 19 Claims
 
1. A composition for intravenous or subcutaneous administration to a human subject in need thereof, comprising:
(1) a biologically active modified relaxin polypeptide, wherein:
(a) said modified relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4, and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 6, and said non-naturally encoded amino acid is substituted in said A chain polypeptide at residue 1; and
(b) said non-naturally encoded amino acid is linked to a linker or polymer, wherein said non-naturally encoded amino acid comprises a first functional group and the linker or polymer comprises a second functional group, wherein the first functional group and second functional group are not identical and each comprise a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises a triazole or an oxime linkage; and
(2) a pharmaceutically acceptable carrier and/or excipient.